Ten percent to 15% of breast and ovarian cancer patients carry germline mutations in HR genes BRCA1 and BRCA2 (Gallagher et al. 2011; Mavaddat et al. 2012; Nik-Zainal et al. 2016). This evidence concerns the gene BRCA1 and ovarian carcinoma.